Skip to main content
SpringerLink
Log in

Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

The plasminogen activation system consists of plasminogen activators and their inhibitors, serine proteases, and serpins. The proteases and inhibitors regulate a variety of processes in tissue morphogenesis, differentiation, cell migration, and cancer cell invasiveness and metastasis. One of the plasminogen activators, urokinase-type plasminogen activator (uPA), binds to a specific surface and provides a localized cell surface proteolytic activity required for the destruction of extracellular matrix, which is a vital step in tumor cell invasion. The proteolytic activity of uPA is modulated by its cell surface receptor, as well as by plasminogen activator inhibitor type-1 (PAI-1) and, to a lesser degree, by other inhibitors.

The role of plasminogen activators and their inhibitors in cancer invasion can be demonstrated in the development and progression of malignant brain tumors. Our findings indicate that uPA and PAI-1 expression are dramatically upregulated in malignant brain tumors in parallel with the histological progression of the tumors. The results suggest that these molecules may contribute to tumor invasion in addition to their significant role in angiogenesis. An evaluation of the plasminogen activation system could add diagnostic and prognostic significance to the evaluation of individual patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336, 1991

    Google Scholar 

  2. Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 88: 1067–1072, 1991

    PubMed  Google Scholar 

  3. Blasi F, Vassalli J-D, Danø K: Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104: 801–804, 1987

    PubMed  Google Scholar 

  4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139–266, 1985

    PubMed  Google Scholar 

  5. Pöllänen J, Stephens RW, Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273–328, 1991

    PubMed  Google Scholar 

  6. Saksela O: Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 823: 35–65, 1985

    PubMed  Google Scholar 

  7. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV: Cloning and expression of human tissue-type plasminogen activator cDNA inE. Coli. Nature 301: 214–221, 1983

    PubMed  Google Scholar 

  8. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nucleric Acids Res 13: 2759–2771, 1985

    Google Scholar 

  9. Laiho M, Keski-Oja J: Growth factors in the regulation of pericelluar proteolysis. A review. Cancer Res 49: 2533–2553, 1989

    PubMed  Google Scholar 

  10. Wolf BB, Vasudevan J, Henkin J, Gonias SL: Nerve growth factor-γ activites soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem 268: 16327–16331, 1993

    PubMed  Google Scholar 

  11. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632–2636, 1989

    PubMed  Google Scholar 

  12. Reich P, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R: Effects of inhibitors of plasminogen activator, serine proteases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307–3312, 1988

    PubMed  Google Scholar 

  13. Hart DA, Rehemtulla A: Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol (B) 90: 691–708, 1988

    Google Scholar 

  14. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K: Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 261: 7644–7651, 1986

    PubMed  Google Scholar 

  15. Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer-Laszuk R, Gelehrter TD: Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 261: 4352–4357, 1986

    PubMed  Google Scholar 

  16. Ellis V, Danø K: Plasminogen activator by receptor-bound urokinase. Semin Thromb Hemost 17: 194–200, 1991

    PubMed  Google Scholar 

  17. Erickson LA, Hekman CM, Loskutoff DJ: The primary plasminogen activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82: 8710–8714, 1985

    PubMed  Google Scholar 

  18. Heidtmann H-H, Hofmann M, Jacob E, Erbil C, Havemann K, Schwartz-Albiez R: Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res 49: 6960–6965, 1989

    PubMed  Google Scholar 

  19. Kooistra T, Sprengers ED, Van Hinsbergh VW: Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem J 239: 497–504, 1986

    PubMed  Google Scholar 

  20. Levin EG, Santell L: Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 70: 1090–1098, 1987

    PubMed  Google Scholar 

  21. Mimuro J, Schleef RR, Loskutoff DJ: Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70: 721–728, 1987

    PubMed  Google Scholar 

  22. Reilly CF, McFall RC: Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 266: 9419–9427, 1991

    PubMed  Google Scholar 

  23. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL, Testuz J, Sordat B: Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87: 6939–6943, 1990

    PubMed  Google Scholar 

  24. Hagège J, Peraldi MN, Rondeau E, Adida C, Delarue F, Medcalf R, Schleuning WD, Sraer JD: Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells. Am J Pathol 141: 117–128, 1992

    PubMed  Google Scholar 

  25. Pöllänen J, Hedman K, Nielsen LS, Danø K, Vaheri A: Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 106: 87–95, 1988

    PubMed  Google Scholar 

  26. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ: The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 110: 155–163, 1990

    PubMed  Google Scholar 

  27. Cubellis MV, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F: Accessibility of receptor-bound urokinase to type 1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 86: 4828–4832, 1989

    PubMed  Google Scholar 

  28. Ellis V, Wun TC, Behrendt N, Rønne E, Danø K: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265: 9904–9908, 1990

    Google Scholar 

  29. Kundsen BS, Harpel PC, Nachman RL: Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 80: 1082–1089, 1987

    PubMed  Google Scholar 

  30. Ossowski L, Russo-Payne H, Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274–281, 1991

    PubMed  Google Scholar 

  31. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021–5025, 1993

    PubMed  Google Scholar 

  32. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS: Modulation ofin vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143–4147, 1993

    PubMed  Google Scholar 

  33. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO: Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 53: 6051–6057, 1993

    PubMed  Google Scholar 

  34. Montgomery AMP, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM: Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53: 693–700, 1993

    PubMed  Google Scholar 

  35. Bergman BL, Scott RW, Bajpai A, Watt S, Baker JB: Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast protease inhibitor, protease nexin I. Proc Natl Acad Sci USA 83: 996–1000, 1986

    PubMed  Google Scholar 

  36. Blasi F: Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15: 105–111, 1993

    PubMed  Google Scholar 

  37. Russel DC, Rubinstein LJ: Pathology of tumors of the nervous system. Edward Arnold, (5 ed) London, 1989

    Google Scholar 

  38. Burger PC, Dubois PJ, Schold SCJr, Smith KRJr, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma maltiforme. J Neurosurg 58: 159–169, 1983

    PubMed  Google Scholar 

  39. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58–61, 1989

    PubMed  Google Scholar 

  40. Goldfarb RH, Ziehe M, Murano G, Liotta LA: Plasminogen activators (Urokinase) mediate neovascularization: possible role in tumor angiogenesis. Semin Thromb Hemost 12: 337–338, 1986

    PubMed  Google Scholar 

  41. Pepper MS, Vassalli J-D, Montesano R, Orci L: Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 105: 2535–2541, 1987

    PubMed  Google Scholar 

  42. Sawaya R: The fibrinolytic enzymes in the biology of brain tumors. In: Sawaya R (ed) Fibrinolysis and the central nervous system. Hanley & Belfus, Inc., Philadelphia, 1990, pp 106–126

    Google Scholar 

  43. Collen D: On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 43: 77–89, 1980

    PubMed  Google Scholar 

  44. Moonen G, Grau-Wagemans MP, Selak I, Lefebvre PP, Rogister B, Vassalli JD, Belin D: Plasminogen activator is a mitogen for astrocytes in developing cerebellum. Brain Res 352: 41–48, 1985

    PubMed  Google Scholar 

  45. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D: Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361: 453–457, 1993

    PubMed  Google Scholar 

  46. Krystosek A, Seeds NW: Plasminogen activator release at the neuronal growth cone. Science 213: 1532–1534, 1981

    PubMed  Google Scholar 

  47. Moonen G, Grau-Wagemans MP, Selak I: Plasminogen activator-plasmin system and neuronal migration. Nature 298: 753–755, 1982

    PubMed  Google Scholar 

  48. Sawaya R, Highsmith R: Plasminogen activator activity and molecular weight patterns in human brain tumors. J Neurosurg 68: 73–79, 1988

    PubMed  Google Scholar 

  49. Sawaya R, Rämö OJ, Shi ML, Mandybur G: Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74: 480–486, 1991

    PubMed  Google Scholar 

  50. de Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijpen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GNP: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathology 144: 70–81, 1994

    Google Scholar 

  51. Ossowski L, Biegel D, Reich E: Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 16: 929–940, 1979

    PubMed  Google Scholar 

  52. Goldfarb RH, Murano G, Brundage R, Siegal GP, Terranova V, Garbisa S, Liotta LA: Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, α-thrombin, and plasmin. Semin Thromb Hemost, 12: 335–336, 1986

    PubMed  Google Scholar 

  53. Ichinose A, Fujikawa K, Suyama T: The activation of prourokinase by plasmin kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486–3489, 1986

    PubMed  Google Scholar 

  54. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266: 5147–5152, 1991

    PubMed  Google Scholar 

  55. Sappino A, Busso N, Belin D, Vassalli JD: Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 47: 4043–4046, 1987

    PubMed  Google Scholar 

  56. Oka T, Ishida T, Nishino T, Sugimachi K: Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 51: 3522–3525, 1991

    PubMed  Google Scholar 

  57. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829, 1990

    PubMed  Google Scholar 

  58. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101–6105, 1992

    PubMed  Google Scholar 

  59. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Møuridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521, 1993

    PubMed  Google Scholar 

  60. Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet ii: 1049, 1989

    Google Scholar 

  61. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA: Type 1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208–214, 1992

    PubMed  Google Scholar 

  62. Schmitt M, Jänicke F, Hafter R, Hollrieder A, Kanayama N, Gulba D, Graeff D (ed): Tumor-associated fibrinolysis in human breast cancer: detection and quantitation of the urokinase-type plasminogen activator (uPA) by ELISA and immunohistochemistry. Amsterdam: Elsevier Science Publishers BY, 1990: 213–222. Matsuda M, Iwanaga S, Takada A, Henschen A (ed) Fibrinogen 4: Current basic and clinical aspects

    Google Scholar 

  63. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50: 345–348, 1992

    PubMed  Google Scholar 

  64. Clayman G, Wang SW, Nicolson GL, El-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd DD: Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer 54: 73–80, 1993

    PubMed  Google Scholar 

  65. Boyd D, Ziober B, Chakrabarty S, Brattain M: Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res 49: 816–820, 1989

    PubMed  Google Scholar 

  66. de Bruin PA, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, van den Ingh HF, Lamers CB: Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48: 4520–4524, 1988

    PubMed  Google Scholar 

  67. Sier CF, Fellbaum C, Verspaget HW, Schmitt M, Griffioen G, Graeff H, Hôfler H, Lamers CB: Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 19: 231–237, 1991

    PubMed  Google Scholar 

  68. Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 291–311, 1992

    PubMed  Google Scholar 

  69. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270–1278, 1988

    PubMed  Google Scholar 

  70. Kirchheimer JC, Wojta J, Christ G, Binder BR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424–5428, 1989

    PubMed  Google Scholar 

  71. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487–498, 1986

    PubMed  Google Scholar 

  72. Ossowski LL:In vivo Invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437–2445, 1988

    PubMed  Google Scholar 

  73. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983

    PubMed  Google Scholar 

  74. Weidner N: The relationship of tumor angiogenesis and metastasis with emphasis on invasive breast carcinoma. In: Weinstein RL (ed) Advances in Pathology and Laboratory Medicine. 101–122. Chicago, IL: Mosby Year Book, Vol 5, 1992

    Google Scholar 

  75. Bacharach E, Itin A, Keshet E:In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in upregulating physiological angiogenesis. Proc Natl Acad Sci USA 89: 10686–10690, 1992

    PubMed  Google Scholar 

  76. Burtin P, Chavanel G, André-Bougaran J, Gentile A: The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. Int J Cancer 39: 170–178, 1987

    PubMed  Google Scholar 

  77. Kohga S, Harvey SR, Weaver RM, Markus G: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787–1796, 1985

    PubMed  Google Scholar 

  78. Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A: Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 43: 5517–5525, 1983

    PubMed  Google Scholar 

  79. Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073–1079, 1991

    PubMed  Google Scholar 

  80. Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, Danø K: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99: 752–757, 1984

    PubMed  Google Scholar 

  81. Grøndahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen O, Lund LR, Danø K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111–117, 1991

    PubMed  Google Scholar 

  82. Pyke C, Kristensen P, Ralfiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067, 1991

    PubMed  Google Scholar 

  83. Danø K, Dabelsteen E, Nielsen LS, Kaltoft K, Wilson EL, Zeuthen J: Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem 30: 1165–1170, 1982

    PubMed  Google Scholar 

  84. Gross JL, Behrens DL, Mullins DE, Kornblith PL, Dexter DL: Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 48: 291–296, 1988

    PubMed  Google Scholar 

  85. Helseth E, Dalen A, Unsgaard G, Vik R: Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line. J Neuro-Oncol 6: 277–283, 1988

    Google Scholar 

  86. Murphy P, Hart DA: Modulation of plasminogen activator and plasminogen activator inhibitor expression in the human U373 glioblastoma/astrocytoma cell line by inflammatory mediators. Exp Cell Res 198: 93–100, 1992

    PubMed  Google Scholar 

  87. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen D, Danø K: Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochem 21: 6410–6415, 1982

    PubMed  Google Scholar 

  88. Presta M, Ennas MG, Torelli S, Ragnotti G, Gremo F: Synthesis of urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in neuronal cultures of human fetal brain: stimulation by phorbol ester. J Neurochem 55: 1647–1654, 1990

    PubMed  Google Scholar 

  89. Sitrin RG, Gyetko MP, Kole KL, McKeever P, Varani J: Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. Cancer Res 50: 4957–4961, 1990

    PubMed  Google Scholar 

  90. Landau BJ, Kwaan HC, Verrusio EN, Brem SS: Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant brain tumors. Cancer Res 54: 1105–1108, 1994

    PubMed  Google Scholar 

  91. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82: 4939–4943, 1985

    PubMed  Google Scholar 

  92. Vassalli JD, Baccino D, Belin D: A cellular binding site for the 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92, 1985

    PubMed  Google Scholar 

  93. Busso N, Belin D, Failly-Crépin C, Vassalli J-D: Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids. J Biol Chem 261: 9309–9315, 1986

    PubMed  Google Scholar 

  94. Medcalf RL, Richards RI, Crawford RJ, Hamilton J: Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids. EMBO J 5: 2217–2222, 1986

    PubMed  Google Scholar 

  95. Emeis JJ, van Hinsberg VW, Verheijen JH, Wijngaards G: Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun 110: 392–398, 1983

    PubMed  Google Scholar 

  96. Levin EG: Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 80: 6804–6808, 1983

    PubMed  Google Scholar 

  97. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D: Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 80: 2956–2960, 1983

    PubMed  Google Scholar 

  98. Gelehrter TD, Barouski-Miller PA, Coleman PL, Cwikel BJ: Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 53/54: 11–21, 1983

    Google Scholar 

  99. Laiho M, Saksela O, Andreasen PA, Keski-Oja J: Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 103: 2403–2410, 1986

    PubMed  Google Scholar 

  100. Kobayashi H, Moniwa N, Gotoh J, Sugimura M, Terao T: Role of activated protein C in facilitating basement membrane invasion by tumor cells. Cancer Res 54: 261–267, 1994

    PubMed  Google Scholar 

  101. Jänicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303–312, 1991

    PubMed  Google Scholar 

  102. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K, Brunner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120–123, 1994

    PubMed  Google Scholar 

  103. Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K: Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93: 559–566, 1990

    PubMed  Google Scholar 

  104. Shirasuna K, Saka M, Hayashido Y, Yoshioka H, Sugiura T, Matsuya T: Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res 53: 147–152, 1993

    PubMed  Google Scholar 

  105. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K: The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51: 4067–4071, 1991

    PubMed  Google Scholar 

  106. Cubellis MV, Wun T-C, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079–1085, 1990

    PubMed  Google Scholar 

  107. Herz J, Clouthier DE, Hammer RE: LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71: 411–421, 1992

    PubMed  Google Scholar 

  108. Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun TC, Appella E, Danø K, Blasi F: Internalization of the urokinase: plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Bio Chem 267: 9129–9133, 1992

    Google Scholar 

  109. Schleef RR, Higgins DL, Pillemer E, Levitt LJ: Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 83: 1747–1752, 1989

    PubMed  Google Scholar 

  110. Aillaud MF, Juhan-Vague I, Alessi MC, Marecal M, Vinson MF, Arnaud C, Vague P, Collen D: Increased PA-inhibitor levels in the postoperative period: no cause-effect relation with increased cortisol. Thromb Haemost 54: 466–468, 1985

    PubMed  Google Scholar 

  111. Almér LO, Ohlin H: Elevated levels of rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 47: 335–339, 1987

    PubMed  Google Scholar 

  112. Colucci M, Paramo JA, Collen D: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75: 818–824, 1985

    PubMed  Google Scholar 

  113. Páramo JA, Alfaro MJ, Rocha E: Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor-relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemost 54: 713–716, 1985

    PubMed  Google Scholar 

  114. Sawaya R, Glas-Greenwalt P: Postoperative venous thromboembolism and brain tumors: part II. Hemostatic profile. J Neuro-Oncology 14: 127–134, 1992

    Google Scholar 

  115. Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ: Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 142: 59–70, 1993

    PubMed  Google Scholar 

  116. Keohane ME, Hall SW, VandenBerg SR, Gonias SL: Secretion of α2-macroglobulin, α2-antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture. J Neurosurg 73: 234–241, 1990

    PubMed  Google Scholar 

  117. Murphy PG, Hart DA: Regulation of plasminogen activator and plasminogen activator inhibitor expression by cells of neural origin. Semin Thromb Hemost 17: 268–275, 1991

    PubMed  Google Scholar 

  118. Rehemtulla A, Murphy P, Dobson M, Hart DA: Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma, U138. Biochem Cell Biol 66: 1270–1277, 1988

    PubMed  Google Scholar 

  119. Wagner SL, Lau AL, Nguyen A, Mimuro J, Loskutoff DJ, Isackson PJ, Cunningham DD: Inhibitors of urokinase and thrombin in cultured neuronal cells. J Neurochem 56: 234–242, 1991

    PubMed  Google Scholar 

  120. Rao JS, Rayford A, Morantz RA, Festoff BW, Sawaya R: Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neuro-Oncology 17: 215–221, 1994

    Google Scholar 

  121. Kono S, Rao JS, Bruner JM, Sawaya R: Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropath Exp Neurology 53: 256–262, 1994

    Google Scholar 

  122. Owensby DA, Morton PA, Wun T-C, Schwartz AL: Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 266: 4334–4340, 1991

    PubMed  Google Scholar 

  123. Schneiderman J, Sawdey M, Craig H, Thinnes T, Bordin G, Loskutoff DJ: Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. Am J Pathol 143: 753–762, 1993

    PubMed  Google Scholar 

  124. Sprengers ED, Kluft C: Plasminogen activator inhibitor. Blood 69: 381–387, 1987

    PubMed  Google Scholar 

  125. D'Amore PA, Thompson RW: Mechanisms of angiogenesis. Annu Rev Physiol 49: 453–464, 1987

    PubMed  Google Scholar 

  126. Keski-Oja J, Koli K, Lohi J, Laiho M: Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemost 17: 231–239, 1991

    PubMed  Google Scholar 

  127. Sawdey M, Podor TJ, Loskutoff DJ: Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α. J Biol Chem 264: 10396–10401, 1989

    PubMed  Google Scholar 

  128. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MAJ, Loskutoff DJ: Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263: 5797–5803, 1988

    PubMed  Google Scholar 

  129. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF: Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489–2496, 1992

    PubMed  Google Scholar 

  130. Frixen UH, Nagamine Y: Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion. Cancer Res 53: 3618–3623, 1993

    PubMed  Google Scholar 

  131. Saksela O, Moscatelli D, Rifkin DB: The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105: 957–963, 1987

    PubMed  Google Scholar 

  132. Mignatti P, Tsuboi R, Robbins E, Rifkin DB:In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 108: 671–682, 1989

    PubMed  Google Scholar 

  133. Ciambrone GJ, McKeown-Longo PJ: Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 267: 13617–13622, 1992

    PubMed  Google Scholar 

  134. Kost C, Stüber W, Ehrlich HJ, Pannekoek H, Preissner KT: Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267: 12098–12105, 1992

    PubMed  Google Scholar 

  135. Christensen U, Holmberg L, Bladh B, Åstedt B: Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Haemost 48: 24–26, 1982

    PubMed  Google Scholar 

  136. Kruithoff EK, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F: Purification and characterization of a plasminogen activator inhibitor from the histocytic lymphoma cell line U-937. J Biol Chem 261: 11207–11213, 1986

    PubMed  Google Scholar 

  137. Åstedt B, Lecander I, Brodin T, Lundblad A, Low K: Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 53: 122–125, 1985

    PubMed  Google Scholar 

  138. Hekman CM, Loskutoff DJ: Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260: 11581–11587, 1985

    PubMed  Google Scholar 

  139. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783–792, 1990

    PubMed  Google Scholar 

  140. Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J: Relationship between cathepsin B, urokinase, and plasminogen activator inhibitors in malignantvs benign breast tumors. Br J Cancer 64: 926–932, 1991

    PubMed  Google Scholar 

  141. Sier CF, Verspaget HW, Griffioen C, Verheijen JH, Quax PH, Dooijewaard G, de Bruin PA, Lamers CB: Imbalance of plasminogen activators and their inhibitors in human colorectal carcinogenesis. Gastroenterology 101: 1522–1528, 1991

    PubMed  Google Scholar 

  142. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, Baba S, Sakaguchi S, Takada Y, Takada A: Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65: 709–719, 1992

    PubMed  Google Scholar 

  143. Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EKO, Lijnen HR, Burtin P: The plasminogen-activation system in ovarian tumors. Int J Cancer 55: 27–31, 1993

    PubMed  Google Scholar 

  144. Cohen RL, Niclas L, Lee WMF, Wun T-C, Crowley CW, Levinson AD, Sadler JE, Shuman MA: Effect of cellular transformation on expression of plasminogen activator inhibitors 1 and 2: evidence for independent regulation. J Biol Chem 264: 8375–8383, 1989

    PubMed  Google Scholar 

  145. Belin D, Wohlwend A, Schleuning WD, Kruithof EK, Vassalli J-D: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor-2. EMBO J 8: 3287–3294, 1989

    PubMed  Google Scholar 

  146. Baker JB, Low DA, Simmer RL, Cunningham DD: Protease-nexin: a cellular compornent that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21: 37–45, 1980

    PubMed  Google Scholar 

  147. McGrogan M, Kennedy J, Li MP, Hsu C, Scott RW, Simonsen C, Baker JB: Molecular cloning and expression of two forms of human protease nexin I. Biotechnology 6: 172–177, 1988

    Google Scholar 

  148. Scott RW, Baker JB: Purification of human protease nexin. J Biol Chem 258: 10439–10444, 1983

    PubMed  Google Scholar 

  149. Gloor S, Odink K, Guenther J, Nick H, Monard D: A glia-derived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. Cell 47: 687–693, 1986

    PubMed  Google Scholar 

  150. Guenther J, Nick H, Monard D: A glia-derived neurite-promoting factor with protease inhibitory activity. EMBO J 4: 1963–1966, 1985

    PubMed  Google Scholar 

  151. Wagner SL, Geddes JW, Cotman CW, Lau AL, Gurwitz D, Isackson PJ, Cunningham DD: Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. Proc Natl Acad Sci USA 86: 8284–8288, 1989

    PubMed  Google Scholar 

  152. Rosenblatt DE, Cotman CW, Nieto-Sampedro M, Rowe JW, Knauer DJ: Identification of a protease inhibitor produced by astrocytes that is structurally and functionally homologous to human protease nexin-I. Brain Res 415: 40–48, 1987

    PubMed  Google Scholar 

  153. Monard D: Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci 11: 541–544, 1988

    PubMed  Google Scholar 

  154. Vaughan PJ, Cunningham DD: Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. J Biol Chem 268: 3720–3727, 1993

    PubMed  Google Scholar 

  155. Cavanaugh KP, Gurwitz D, Cunningham DD, Bradshaw RA: Reciprocal modulation of astrocytes stellation by thrombin and protease nexin-1. J Neurochem 54: 1735–1743, 1990

    PubMed  Google Scholar 

  156. Rao JS, Baker JB, Morantz RA, Kimler B, Evans R, Festoff BW: Serpin inhibitors of urokinase and thrombin in normal rat brain and 9L brain tumor: evidence for elevated expression of protease nexin 1-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. Cancer Res 50: 5039–5044, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Masaaki Yamamoto, Raymond Sawaya, Sanjeeva Mohanam & Jasti S. Rao

  2. Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Janet M. Bruner

  3. Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Garth L. Nicolson

  4. Connective Tissue Laboratory, Meyer Rehabilitation Institute, Omaha, Nebraska

    Velidi H. Rao

  5. Department of Pathology, Fukuoka University School of Medicine, Fukuoka, Japan

    Kohichi Ohshima

Authors
  1. Masaaki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond Sawaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanjeeva Mohanam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Velidi H. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janet M. Bruner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Garth L. Nicolson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kohichi Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jasti S. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, M., Sawaya, R., Mohanam, S. et al. Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. J Neuro-Oncol 22, 139–151 (1994). https://doi.org/10.1007/BF01052889

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01052889

Key words

Search

Navigation